GlassScriptPhysician profile
Karen Lazzaro
NPI 1427026954
$3,154.59
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $413 · 2021: $458 · 2022: $553 · 2023: $713 · 2024: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.90 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.46 | 2019-2024 | |
| Pfizer INC. | $382.30 | 2019-2024 | |
| Lilly USA, LLC | $248.02 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $197.03 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.46 | 2020-2023 | Stiolto Respimat, Spiriva Respimat |
| Astellas Pharma US INC | $161.26 | 2019-2023 | |
| Amgen INC. | $156.33 | 2019-2021 | |
| Novo Nordisk INC | $149.02 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $144.31 | 2019-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $134.94 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $113.93 | 2019-2023 | Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $110.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.06 | 2022-2024 | |
| Abbott Laboratories | $85.20 | 2023 | Proclaim |
| Sanofi-Aventis U.S. LLC | $61.43 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $55.15 | 2019-2021 | |
| Boston Scientific Corporation | $48.52 | 2022-2024 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.25 | 2021-2024 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $31.80 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $30.79 | 2022 | |
| Dexcom, INC. | $29.42 | 2021 | |
| Eisai INC. | $25.55 | 2021 | |
| Exact Sciences Corporation | $23.42 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $22.88 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $19.46 | 2022 | |
| Shield Therapeutics INC | $15.48 | 2024 | |
| Currax Pharmaceuticals LLC | $15.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.63 | 2019 | |
| Biogen, INC. | $13.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.07 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Lazzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.